Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

Table 1 Characteristics and quality of randomized control trials comparing bisphosphonates users and controls with regard to atrial fibrillation

Author, year	*Studies included in reports (Ref)	Publication	N	†AF/BP users versus AF/non-BP users	Age (mean)	Study duration (years)	Jadad score (1-5)
Black, 2007	NA	Full text	7714	94/3862 versus 73/3852	73	3	4
Cummings, 2007	Black, 1996^a (27)	Letter to the	2027	81/3236 versus	70.8	3	4
	Cummings, 1998^a (28)	editor	4432	71/3223	67.7	4.2	3
Lyles, 2007	NA	Full text	2111	29/1054 versus 27/1057	74.5	5	4
Karam, 2007	Combination of trials ^b	Letter to the editor	15066	Summary: 189/10018 versus 94/5048	73.5	NA	NA
Papapoulous, 2008	Chesnut, 2005 (30)		2929		68.7	3	3
	Recker, 2004 (31)	Abstract	2860	Summary:	67	3	4
	Reginster, 2006 (32)		1583	57/6830 versus 18/1924	66	2	4
	Eisman, 2008 (33)		1382		65.9	2	4

*Randomized controlled trials included in letters to the editor and abstracts
† Number of cases of AF in bisphosphonate users versus number of cases of AF in non-bisphosphonate users
^a Two Fracture Intervention Trials
^b Involved trials: Vertebral Efficacy with Risedronate Therapy Trial, the Bone Mineral Density Trial, the Risedronate
5 mg Daily Prevention Trial, the Glucocorticosteroid - Induced Osteoporosis Prevention and Treatment Trials and the
Hip Intervention Program Trial
Abbreviations: Ref, references; N, number of patients; AF, atrial fibrillation; BP, bisphosphonates; NA, not applicable

ISSN: 1471-2474